2 Longleng villages declared ASF-infected zones
The DC made the declaration following a report from the office of the chief veterinary officer of Longleng confirming the occurrence of the disease in the two villages.
Phom declared a one km radius of the two infected villages as infected zones and 10 km radius from the infected areas as surveillance zones to control and contain the ASF outbreak.
To control the spread of disease, the district administration has also banned slaughter of pigs, import and export of pigs and piglets and transportation of pigs and pork.
Meanwhile, Longleng additional deputy commissioner Alongdhimen Jamir on Thursday prohibited dumping, abandoning, or disposing of animal carcasses at the Longleng Town Council's municipal dumping site or any undesignated open space within the municipal limits.
The ADC imposed the ban following reports of unlawful dumping of animal carcasses, including pigs and other animals, at the dumping site, leading to significant public health hazards and environmental pollution.
He said any violation of the order will result in legal penalties.
He reminded that in accordance with the guidelines set by the Central Pollution Control Board (CPCB), animal carcasses must be disposed of using scientifically approved methods, such as incineration or deep burial, to minimise health risks and prevent environmental damage.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 days ago
- Time of India
Cohance to invest Rs 110 crore in new facilities in Hyderabad and New Jersey
Hyderabad: Cohance Lifesciences Limited, backed by PE giant Advent International, is investing Rs 110 crore in its facilities in Hyderabad and New Jersey. This includes $10 million (approx. Rs 87 crore) in expanding its cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and Rs 23 crore in its new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The new facility in Hyderabad, Cohance said, will enable it to take high-value chemistries like modified nucleosides and locked nucleic acids (LNA) from laboratory scale to full commercial manufacturing to fulfil the needs of innovators advancing oligonucleotide-based therapeutics. The Hyderabad-based company mentioned that the Hyderabad plant, integrated with a pilot plant for early-stage synthesis and non-GMP scale-up, will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad | Gold Rates Today in Hyderabad | Silver Rates Today in Hyderabad The company said the US investment will significantly enhance its capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions. The strategic investment in Hyderabad will strengthen its integrated oligonucleotide platform and boost its prospects as a preferred partner for emerging modalities by enhancing its ability to support innovators from early development through late-phase clinical supply. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Once back of the pack, Chinese running shoes now look to surge ahead in S'pore market CNA Read More Undo The two investments are part of its planned capacity expansion programme across high-growth modalities, which would enhance its ability to serve global innovators from early development to commercial supply, the company said. Cohance Lifesciences Executive Chairman Vivek Sharma said: "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics. " Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Time of India
4 days ago
- Time of India
Cohance Lifesciences announces $10 million investment in US-based arm
Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio . The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top 32 Most Beautiful Women In The World Undo "The investment ... strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad . Live Events "Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals , is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.
News18
5 days ago
- News18
Cohance Lifesciences announces USD 10 mn investment in US-based arm
New Delhi, Aug 12 (PTI) Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio. The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. 'The investment … strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad. 'Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. PTI MSS MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
